A newly published clinical case report in BMC Neurology documents a rare presentation of progressive demyelinating sensorimotor polyneuropathy in a 53-year-old woman undergoing treatment for advanced breast cancer with eribulin mesylate. Chemotherapy-induced peripheral neuropathy is a well-recognized complication commonly associated with eribulin administration, but the condition typically manifests in an axonal pattern. In contrast, demyelinating neuropathy linked to eribulin therapy is exceedingly rare across clinical practice, with only limited case reports published in medical literature to date. The patient described in the report experienced substantial neurological and clinical recovery following targeted intervention, offering important insights into this atypical manifestation.
The patient developed progressive sensorimotor neuropathy after completing six cycles of eribulin therapy. Her initial presentation was marked by ascending distal paresthesia affecting both lower limbs. Over the subsequent course of her illness, this sensory disturbance was followed by symmetrical distal weakness that progressed to bilateral foot drop, as well as subsequent distal upper-limb weakness that developed within two months. A detailed neurological examination identified generalized hypotonia alongside predominantly distal weakness, evaluated at Medical Research Council grade 2 distally and grade 4 proximally. Physical evaluation further confirmed length-dependent sensory loss to pinprick and vibration sensations, while proprioception remained preserved, and generalized areflexia was documented across all tested reflexes.
At the time of baseline clinical evaluation, the patient demonstrated significant functional impairment, reflected in an initial Inflammatory Neuropathy Cause and Treatment (INCAT) disability score of 8, with an upper-limb score of 4 and a lower-limb score of 4. Comprehensive electrodiagnostic testing through nerve conduction studies confirmed the presence of a sensorimotor polyneuropathy displaying prominent demyelinating features. These electrophysiological findings included marked conduction slowing and conduction block, alongside substantial axonal involvement. Further diagnostic evaluations were undertaken to investigate possible alternative etiologies: cerebrospinal fluid (CSF) analysis proved unremarkable and demonstrated no albuminocytologic dissociation, while magnetic resonance imaging (MRI) of the brain and entire spine revealed no abnormal findings. In addition, serological testing confirmed that nodal and paranodal antibodies were negative.
To exclude other potential underlying causes, extensive laboratory investigations evaluated paraneoplastic and autoimmune antibody markers across both serum and cerebrospinal fluid samples, all of which returned negative results. In response to the diagnosis, eribulin therapy was discontinued immediately, and immunosuppressive medical management was initiated with high-dose intravenous methylprednisolone administered at 1 gram per day for 5 consecutive days. This acute intravenous course was followed by a regimen of tapering oral prednisolone. The patient demonstrated marked neurological improvement within three weeks of starting therapy. By three months of follow-up, she was independently ambulatory and fully independent in activities of daily living, with her total INCAT disability score improving to 2, comprising a score of 1 for the upper limbs and 1 for the lower limbs.
In their clinical conclusion, the study authors noted that eribulin may rarely be associated with an atypical pattern of chemotherapy-induced peripheral neuropathy characterized by prominent demyelinating features and substantial axonal involvement, which stands distinct from the conventional, predominantly axonal pattern usually observed. The authors emphasized several key limitations of the findings, explaining that a definitive causal relationship and the precise underlying biological mechanisms cannot be firmly established based on a single case presentation. Furthermore, the potential contribution of pre-existing axonal neuropathy resulting from previous chemotherapy regimens cannot be completely excluded. Nonetheless, the authors observed that early clinical recognition, prompt discontinuation of eribulin, and appropriate therapeutic management may be associated with substantial neurological recovery in affected patients.
Subject of Research: Eribulin-associated demyelinating sensorimotor polyneuropathy and clinical recovery
Article Title: Eribulin-associated demyelinating sensorimotor polyneuropathy with substantial clinical recovery: a case report
Article References: Panja, P., Tovanabutra, P., & Pornchaisakuldee, N. (2026). Eribulin-associated demyelinating sensorimotor polyneuropathy with substantial clinical recovery: a case report. BMC Neurology. https://doi.org/10.1186/s12883-026-05591-0
Image Credits: AI Generated
DOI: 10.1186/s12883-026-05591-0
Keywords: eribulin, chemotherapy-induced peripheral neuropathy, demyelinating polyneuropathy, breast cancer, sensorimotor neuropathy, methylprednisolone, case report, neurology, Eribulin-associated, demyelinating, sensorimotor, polyneuropathy
News Source: Ophelia Keating. (November 10, 2026). Eribulin Linked to Rare Demyelinating Sensorimotor Polyneuropathy in Case Report. Scienmag.



